...
首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report 7
【24h】

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report 7

机译:卫生经济学的方法对我们来说价值评估Frameworks-Summary和建议的ISPOR特别工作组报告7

获取原文
获取原文并翻译 | 示例

摘要

This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e.g., insurance value and equity) as part of either an "augmented" cost-effectiveness analysis or a multicriteria decision analysis. Given an aggregation of elements to a measure of value, consistent use of a cost-effectiveness threshold can help ensure the maximization of health gain and well-being for a given budget. These decisions can benefit from the use of deliberative processes. The six recommendations are to: 1) be explicit about decision context and perspective in value assessment frameworks; 2) base health plan coverage and reimbursement decisions on an evaluation of the incremental costs and benefits of health care technologies as is provided by cost-effectiveness analysis; 3) develop value thresholds to serve as one important input to help guide coverage and reimbursement decisions; 4) manage budget constraints and affordability on the basis of cost-effectiveness principles; 5) test and consider using structured deliberative processes for health plan coverage and reimbursement decisions; and 6) explore and test novel elements of benefit to improve value measures that reflect the perspectives of both plan members and patients.
机译:这部分首先列出要点总结每六个部分的报告由六个主要建议。强迫选择卫生经济学的方法健康计划是否应该的问题封面和偿还特定的技术,认为传统的开始cost-per-quality-adjusted生命指标有优势作为起点和认可的局限性。更全面的经济的发展评价,其中可能包括小说的元素值(例如,保险价值和股票)的部分一个“增强”的成本效益分析或多准则决策分析。给定一个聚合的元素来衡量的价值,一致的使用成本效益阈值可以帮助确保的最大化获得健康和幸福对于一个给定的预算。这些决策可以受益于使用协商过程。是:1)明确决策上下文和呢视角的价值评估框架;基础医疗计划覆盖和报销决定一个评估的增量医疗技术的成本和效益提供成本效益分析;阈值作为一个开发价值重要的帮助指导覆盖率和输入报销的决定;约束和支付能力的基础上成本效益原则;考虑使用结构化的协商过程卫生计划覆盖和报销决定;有利于改善措施,体现价值计划成员和两个方面病人。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号